

CITATION REPORT

List of articles citing

Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

DOI: 10.1016/s0140-6736(01)06004-4
Lancet, The, 2001, 358, 813-4.

Source: <https://exaly.com/paper-pdf/32478385/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
130	Current World Literature. 2002 , 14, 619-634		
129	Antimalarial agents in pregnancy. <i>Lancet, The</i> , 2002 , 359, 524-5	40	46
128	[Systemic sclerosis and pregnancy]. 2002 , 23, 607-21		8
127	[Kidney, lupus and pregnancy]. 2002 , 23, 813-8		2
126	Current awareness in pharmacoepidemiology and drug safety. 2002 , 11, 169-74		
125	Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. 2003 , 48, 3207-11		228
124	Effects of chloroquine on viral infections: an old drug against today's diseases?. 2003 , 3, 722-7		854
123	Neonatal outcome in patients with rheumatic disease. 2004 , 13, 718-23		17
122	Systemic lupus erythematosus in pregnancy. 2004 , 6, 80-87		4
121	Disseminated Salmonella typhimurium infection secondary to infliximab treatment. 2004 , 50, 3049		19
120	Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al. 2004 , 50, 3049-50; author reply 3050-1		7
119	Reply. 2004 , 50, 3050-3051		
118	Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al. 2004 , 50, 3051; author reply 3051-2		2
117	Reply. 2004 , 50, 3051-3052		3
116	Radiographic progression in early rheumatoid arthritis: comment on the article by Goronzy et al. 2004 , 50, 3052-3; author reply 3053-4		
115	Reply. 2004 , 50, 3053-3054		1
114	Ultrasonography of the shoulder in patients with rheumatoid arthritis: comment on the article by Hermann et al. 2004 , 50, 3054; author reply 3055-6		3

113	Reply. 2004 , 50, 3055-3056	1
112	Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. 2004 , 50, 3056-7; author reply 3057-8	32
111	Reply. 2004 , 50, 3057-3058	11
110	Elective pregnancy termination and microchimerism: comment on the article by Khosrotehrani et al. 2004 , 50, 3058-9; author reply 3059	6
109	Reply. 2004 , 50, 3059-3059	
108	Causes of familial aggregation of fibromyalgia: comment on the article by Arnold et al. 2004 , 50, 3059-60; author reply 3060	4
107	Reply. 2004 , 50, 3060-3060	1
106	Antimalarial drug toxicity: a review. 2004 , 27, 25-61	335
105	Malaria chemoprophylaxis: when should we use it and what are the options?. 2004 , 2, 119-32	27
104	Avaliaço dos efeitos adversos desencadeados pelo uso de difosfato de cloroquina, com ênfase na retinotoxicidade, em 350 doentes com lpus eritematoso. 2005 , 80, S275-S282	2
103	Prenatal transfer of anticardiolipin antibodies associated with fatal neonatal aortic thrombosis. 2005 , 45, 175-6	6
102	Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. 2005 , 25, 86-9	101
101	Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. 2005 , 4, 111-5	101
100	Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome. 2005 , 4, 423-8	43
99	Antimalarials. 2005 , 347-372	
98	O uso de drogas anti-reumticas na gravidez. 2005 , 45, 124	3
97	Use of Anti-Rheumatic Drugs in Pregnancy. 2005 , 4, 101-110	1
96	Cutaneous Lupus Erythematosus. 2005 ,	11

95	[Pleading to maintain hydroxychloroquine throughout Lupus pregnancies]. 2005 , 26, 467-9	4
94	Pregnancy and Systemic Lupus Erythematosus. 2005 , 4, 43-57	
93	Anti-inflammatory and immunosuppressive drugs and reproduction. 2006 , 8, 209	373
92	Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future. 2006 , 29, 845-63	16
91	[Antimalarials: an update in rheumatic diseases]. 2006 , 2, 190-201	8
90	Spezielle Arzneimitteltherapie in der Schwangerschaft. 2006 , 33-557	
89	Hydroxychloroquine in lupus pregnancy. 2006 , 54, 3640-7	362
88	Quinoline antimalarials as investigational drugs for HIV-1/AIDS: in vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations. 2006 , 67, 806-817	10
87	Alternative modified infant-feeding practices to prevent postnatal transmission of human immunodeficiency virus type 1 through breast milk: past, present, and future. 2006 , 22, 75-88; quiz 89-93	16
86	Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. 2006 , 1, 225-233	5
85	Analgesics and anti-inflammatory drugs. 2007 , 28-56	
84	Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. 2007 , 30, 297-308	259
83	Ocular toxicity of hydroxychloroquine. 2008 , 23, 201-9	74
82	Management of early aggressive rheumatoid arthritis during pregnancy and lactation. 2009 , 10, 1469-79	6
81	Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. 2009 , 98, 1500-3	19
80	Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. 2009 , 7, 9	77
79	Management of RA medications in pregnant patients. 2009 , 5, 382-90	100
78	Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). 2010 , 4, 1151-8	83

77	Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. 2010 , 19, 675-82	32
76	Treatment of cutaneous lupus erythematosus. 2010 , 19, 1125-36	33
75	The management of rheumatic diseases in pregnancy. 2010 , 39, 99-108	35
74	Correction. 2010 , 69, 28-28	1
73	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312	1
72	Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. 2010 , 6, 431-40; quiz 441-2	30
71	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. 2010 , 69, 20-8	645
70	Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. 2011 , 7, 1153-67	39
69	Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. 2011 , 71, 1973-87	56
68	Pregnancy and Reproductive Concerns in Systemic Lupus Erythematosus. 2011 , 655-672	1
67	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. 2011 , 10, 705-14	61
66	Antimalarials and SLE. 2011 , 1061-1081	0
65	Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. 2011 , 38, 2504-8	50
64	Update of the management of rheumatoid arthritis in pregnancy. 2012 , 7, 77-96	3
63	Spezielle Arzneimitteltherapie in der Schwangerschaft. 2012 , 33-574	
62	A Case of Hydroxychloroquine Retinopathy. 2012 , 53, 1357	
61	Hydroxychloroquine: from malaria to autoimmunity. 2012 , 42, 145-53	348
60	Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. 2013 , 26, 354-63	31

59	Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. 2013 , 39, 58-62	47
58	Pregnancy in Women with SLE. 2013 , 455-463	1
57	[Hydroxychloroquine during pregnancy: a review of retinal toxicity in the newborns]. 2013 , 68, 43-7	7
56	Fetal pharmacotherapy 2: fetal arrhythmia. 2013 , 35, 1023-1027	
55	Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques. 2014 , 30, 355-62	12
54	Pharmacology of Chloroquine and Hydroxychloroquine. 2014 , 35-63	65
53	Antipalúdicos en dermatologá: mecanismo de acci3n, indicaciones y efectos secundarios. 2014 , 105, 243-252	27
52	Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. 2014 , 70, 401.e1-14; quiz 415	115
51	Prevention of Malaria in Travelers: Bite Avoidance and Chemoprophylactic Measures. 2014 , 6, 47-57	1
50	Contraception and Pregnancy in Patients with Rheumatic Disease. 2014 ,	3
49	Antimalarials in dermatology: mechanism of action, indications, and side effects. 2014 , 105, 243-52	14
48	Hydroxychloroquine: a multifaceted treatment in lupus. 2014 , 43, e167-80	101
47	Immunosuppression, rheumatic diseases, multiple sclerosis, and Wilson's disease. 2015 , 341-372	1
46	A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. 2015 , 49, 317-26	77
45	Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. 2015 , 24, 1384-91	69
44	High-risk pregnancy and the rheumatologist. <i>Rheumatology</i> , 2015 , 54, 572-87	3.9 52
43	Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. 2016 , 88, 2170-2178	25
42	Treatment of rheumatoid arthritis during pregnancy: present and future. 2016 , 12, 937-44	26

41	Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. 2016 , 81, 835-48		56
40	Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. 2016 , 34, 344-52		17
39	Drug safety: Pregnancy rating classifications and controversies. 2016 , 34, 401-9		10
38	Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era. 2018 , 31, 361-383		14
37	Systemic Lupus Erythematosus and Antiphospholipid Syndrome. 2018 , 873-889		
36	Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding. 2018 , 20, 511-521		7
35	C. 2019 , 91-186		1
34	H. 2019 , 357-377		
33	Pregnancy and Autoimmune Disease, Reproductive and Hormonal Issues. 2019 , 499-519		3
32	Risk of Ocular Anomalies in Children Exposed In Utero to Antimalarials: A Systematic Literature Review. 2019 , 71, 1606-1610		8
31	Dose Optimization of Chloroquine by Pharmacokinetic Modeling During Pregnancy for the Treatment of Zika Virus Infection. 2019 , 108, 661-673		15
30	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 3001-3013	4.4	15
29	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. <i>Scientific Reports</i> , 2020 , 10, 22139	4.9	41
28	Sicherheitsmanagement der Therapie mit Antimalariamitteln: was bedeuten die neuen Empfehlungen für die Praxis?. <i>Aktuelle Rheumatologie</i> , 2020 , 45, 314-318	0.1	
27	SARS-CoV-2 in the context of past coronaviruses epidemics: Consideration for prenatal care. <i>Prenatal Diagnosis</i> , 2020 , 40, 1641-1654	3.2	6
26	[Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search]. <i>Zeitschrift Fur Rheumatologie</i> , 2020 , 79, 186-194	1.9	6
25	Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 80, 1-9	1.9	13
24	Antimalarial Agents. 2021 , 234-244.e4		1

23	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 13-24	2.8	9
22	Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. <i>Trends in Molecular Medicine</i> , 2021 , 27, 152-171	11.5	6
21	Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. <i>Rheumatology</i> , 2021 , 60, 2317-2326	3.9	4
20	COVID-19 in pregnancy and the puerperium: A review for emergency physicians. <i>American Journal of Emergency Medicine</i> , 2021 , 40, 193-198	2.9	8
19	Neurobehavioral, neurochemical and synaptic plasticity perturbations during postnatal life of rats exposed to chloroquine in-utero. <i>Neurotoxicology and Teratology</i> , 2021 , 86, 106982	3.9	0
18	Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. <i>Safety Science</i> , 2020 , 129, 104842	5.8	13
17	Unconventional secretion of FABP4 by endosomes and secretory lysosomes. <i>Journal of Cell Biology</i> , 2018 , 217, 649-665	7.3	41
16	Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective. <i>Frontiers in Neurology</i> , 2020 , 11, 596528	4.1	1
15	Pregnancy and the Rheumatic Diseases. 2004 , 429-449		
14	Collagen Vascular Diseases. 2007 , 1080-1103		
13	Life-Threatening Dermatoses Occurring During Gestation. 2009 , 175-180		
12	Pregnancy and Autoimmune Rheumatic Disease. 2010 , 627-644		
11	Drugs and pregnancy. 2011 , 611-616.e2		
10	Autoimmune Diseases. 2011 , 763-794.e8		1
9	Systemic Lupus Erythematosus and Antiphospholipid Syndrome. 475-486		
8	Rhumatologie. 2012 , 235-243		
7	Pregnancy in the Rheumatic Diseases. 2013 , 540-558.e3		
6	Long-Term Outcome of Children of Rheumatic Disease Patients. 2014 , 289-303		1

5	Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. <i>Canadian Family Physician</i> , 2007 , 53, 409-12	0.9	9
4	Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations. <i>Journal of Personalized Medicine</i> , 2022 , 12, 796	3.6	0
3	Antimalarial agents. 2013 , 241-251.e3		3
2	Ocular side effects of drugs administered systemically for treatment of nonocular diseases. 2022 , 491-507		
1	Chloroquine regulates the proliferation and apoptosis of palate development on mice embryo by activating P53 through blocking autophagy in vitro.		